Subcutaneous Injection of Epidermal Growth Factor for Skin Hydrofluoric Acid Burns
Yunanhai Zhang,Liangfang Ni,Xingang Wang,Chunmao Han
DOI: https://doi.org/10.1111/iwj.12306
2014-01-01
International Wound Journal
Abstract:With great interest, we read the recent article published by Songur et al. 1. In this article, the authors have compared the effect of epidermal growth factor (EGF) injection on skin hydrofluoric acid (HF) burns with those of magnesium sulphate and calcium gluconate injections, indicating that EGF limited HF damage morphologically and histologically, more effectively than Ca2+ or Mg2+. These results are encouraging and of major interest. Although subcutaneous injection of EGF certainly has the potential to be a better method for skin HF treatments, we have some concerns about the interpretation of the results. As known, HF is a hazardous inorganic acid, which causes not only corrosive effects on topical tissues but also systemic toxicity 2, 3. The severity of HF burns is closely associated with the concentration of HF, the duration of contact and the characteristics of the topical tissues involved 4, 5. The critical procedure to treat HF burn is to prevent on-going HF absorption and block the progressive destruction caused by fluoride ions 6. The common neutralising agents include calcium gluconate, magnesium sulphate and some other chelating agents. To date, topical application of calcium gluconate gel is a recommended therapy in the first aid of HF burns 7, 8. Due to poor tissue penetrability of calcium and magnesium ions, topical application can neutralise fluoride ions only on or in the superficial layers of the skin. Subcutaneous injection of calcium/magnesium agents, partially overcoming the limitations of external application, is suitable for skin sites with soft tissue and for patients with extensive HF burns or those insensitive to topical application. The dose of chelating agents delivered by subcutaneous injection can be very critical for the effective treatment of skin HF burns. In clinical practice, 10% calcium gluconate is recommended for use as injection treatment at 0·5 ml/cm2 9, 10. However, the accurate dose of calcium gluconate used in this article is not provided for some reason. It is the responsibility of the authors to provide detailed information and further clarify what criteria have been used to determine the injection dose of calcium, magnesium agents and EGF. In this study, the authors took the changes in rat body weight to evaluate fluid loss. It is worth noting whether this method is suitable. The authors have specified the method used to measure the body weights of rats but have not given any information regarding the feeding of the experimental animals post-burn. It is known that intensive pain can be caused by HF burns. Pain has the potential to affect the rats' emotions, feeding habits and changes in body weights. As the treatment modalities mentioned in this article could produce different levels of pain relief, it will be objective to further assess the fluid loss by measuring the amount of intake and output of the rats. Finally, compared with the inorganic ions, EGF as a bioactive factor must play a more positive role in the tissue responses unless deactivated. In this article, the readers could refer to the explanations on the chelating role and mechanism of EGF in HF burns, rather than its role in wound healing. However, a chelating agent such as EGF is welcome because of its positive role in the prevention of HF damage and in wound healing. Yunanhai Zhang & Liangfang Ni Department of Burns and Plastic Surgery Quhua Hospital of Zhejiang Quzhou, China Xingang Wang & Chunmao Han Department of Burns & Wound Care Center 2nd Affiliated Hospital of Zhejiang University, College of Medicine Hangzhou, China wxg8157@gmail.com